Canada markets open in 38 minutes

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1800-0.0150 (-7.69%)
At close: 09:30AM EST
Full screen
Previous Close0.1950
Open0.1800
Bid0.1400 x N/A
Ask0.1700 x N/A
Day's Range0.1800 - 0.1800
52 Week Range0.1150 - 0.2500
Volume3,000
Avg. Volume26,302
Market Cap12.569M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

    VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time. Rakovina invites individual and institutional investors as well as advisors and

  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update. Corporate Update Rakovina Therapeutics has continued to communicate progress in the Company’s research and development programs through presentations at pee

  • GlobeNewswire

    Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

    Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), today announced publication of a scientific article on the anti-cancer activity of the Company’s novel dual PARP-HDAC inhibitor in models of Ewing sarcoma. The manuscript entitled “A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma”, indicate a bene